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Abstract: Botulinum neurotoxins (BoNTs) exhibit extraordinary potency due to their exquisite
neurospecificity, which is achieved by dual binding to complex polysialo-gangliosides and synaptic
vesicle proteins. The luminal domain 4 (LD4) of the three synaptic vesicle glycoprotein 2 isoforms,
SV2A-C, identified as protein receptors for the most relevant serotype BoNT/A, binds within the
50 kDa cell binding domain HC of BoNT/A. Here, we deciphered the BoNT/A-SV2 interactions
in more detail. In pull down assays, the binding of HCA to SV2-LD4 isoforms decreases from
SV2C >> SV2A > SV2B. A binding constant of 200 nM was determined for BoNT/A to rat SV2C-LD4
in GST pull down assay. A similar binding constant was determined by surface plasmon resonance
for HCA to rat SV2C and to human SV2C, the latter being slightly lower due to the substitution L563F
in LD4. At pH 5, as measured in acidic synaptic vesicles, the binding constant of HCA to hSV2C is
increased more than 10-fold. Circular dichroism spectroscopy reveals that the quadrilateral helix of
SV2C-LD4 already exists in solution prior to BoNT/A binding. Hence, the BoNT/A-V2C interaction
is of different nature compared to BoNT/B-Syt-II. In particular, the preexistence of the quadrilateral
β-sheet helix of SV2 and its pH-dependent binding to BoNT/A via backbone–backbone interactions
constitute major differences. Knowledge of the molecular details of BoNT/A-SV2 interactions drives
the development of high affinity peptides to counteract BoNT/A intoxications or to capture functional
BoNT/A variants in innovative detection systems for botulism diagnostic.
Keywords: botulinum neurotoxin; rat and human synaptic vesicle glycoprotein 2; gangliosides;
binding constant; surface plasmon resonance
1. Introduction
Botulinum neurotoxins (BoNTs) produced by the bacteria Clostridium botulinum are the most
poisonous protein toxins known [1]. The y cause the disease botulism due to blockade of acetylcholine
release at the neuromuscular junction. Because of their muscle-relaxing properties BoNTs are also
extensively used in medical and cosmetic applications [2]. The seven serologically different BoNT
serotypes, A to G, comprise four domains, which play individual roles in the intoxication mechanism [3,4].
BoNTs are 150 kDa AB-protein toxins that are composed of a 50 kDa light chain (LC) linked by a
disulfide bridge to the heavy chain (HC), the latter being divided into three independent domains:
HN (50 kDa translocation domain, N-terminus of HC), HCN and HCC (25 kDa each). The latter two
domains constitute the HC-fragment and are responsible for neuronal binding [5].
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Here, the initial low affinity binding to complex polysialo-gangliosides and subsequent
high affinity binding to different synaptic vesicle protein receptor takes place [5]. After the
receptor-mediated endocytosis the synaptic vesicle (SV) acidifies inducing the BoNT to change its
conformation and presumably inserting a pore or channel into the vesicle membrane. The LC, a
Zn2+-metalloprotease, is translocated through the pore formed by the HN domain into the cytosol of
the cell and is released after reduction of the disulfide bridge connecting LC and HC [6]. Here, the
hydrolysis of a specific soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE)
protein takes place; in the case of BoNT/A, synaptosome-associated protein of 25 kDa (SNAP-25)
is specifically cleaved at Q197-R198 [7,8]. This cleavage results in inhibition of the neurotransmitter
release into the synaptic cleft leading to flaccid paralysis, and eventually to death by respiratory failure.
BoNT/A, B, E, F and G all possess a single ganglioside binding site (GBS) comprising the
conserved E(Q) . . . H(K) . . . SxWY . . . G motif [9–11], which specifically recognizes the GalNAc3–Gal4
moiety of complex polysialo-gangliosides albeit with submicromolar affinity [12–14]. In addition,
synaptotagmin-I and -II (Syt-I/-II) serve as protein receptors for BoNT/B, G and the mosaic
BoNT/DC [15–21], whereas the three isoforms of the synaptic vesicle glycoprotein 2 (SV2A-C)
were identified as protein receptors for BoNT/A [22,23]. Furthermore, glycosylated SV2A and B
exclusively serve as protein receptors for BoNT/E [24]. All three SV2 isoforms were also reported to be
co-precipitated by BoNT/D and F from synaptic vesicle lysates, but a direct protein–protein interaction
has not been demonstrated so far [10,25,26].
The three identified highly homologous isoforms SV2A, B and C comprise twelve putative,
conserved transmembrane domains (TMD; Figure 1A), are localized in synaptic vesicles and
neuroendocrine secretory granules of vertebrates [27], but are differently expressed in the brain [28].
Only the luminal domain 4 (LD4) connecting TMD 7 and 8 of all three SV2 isoforms interacts with
BoNT/A HC [22,23]. The human (h) SV2C-LD4 folds into a right-handed, quadrilateral β-helix
(Figure 1B) [29]. The corresponding binding site of SV2C within BoNT/A was allocated to the
interface of HCN and HCC [29,30] while the Syt binding site locates at the tip of the BoNT/B, G and
DC HCC domains in close proximity to the single GBS [11,31–33]. In contrast, the SV2C-binding site is
found almost opposite to the GBS with a distance of approximately 40 Å. hSV2C binds BoNT/A mainly
through backbone-to-backbone interactions at open β-strand edges. In BoNT/A, the amino acids
T1145/46, R1156, G1292 and R1294 play an important role in this interaction [29,30]. The co-crystal
structure reveals that F563 of hSV2C mediates an important cation–π-stacking interaction with R1156
of BoNT/A (Figure 1B) [29], which, however, is unique to human, chimpanzee and chicken SV2C
(Y563 in dog and zebra fish SV2C; H563 in puffer fish; L563 in mouse, rat, bovine; I563 in elephant;
M563 in platypus; A563 in camel; T563 in frog; S563 in rabbit; K563 in turtle; D563 in alligator) [34].
The homologous residue 577 of SV2A and 519 of SV2B is a leucine conserved in human, rat, mouse,
porcine, dog and bovine (M519 in chicken SV2B).
In this study, we further characterized the protein–protein interaction of BoNT/A with its protein
receptors SV2A-C. The LD4 of rSV2A-C and hSV2C were expressed as glutathione-S-transferase
(GST) fusion proteins and hSV2C was also expressed as His-tagged fusion protein in Escherichia coli (E.
coli). GST pull down experiments showed that BoNT/A binds preferable to rSV2C-LD4 lacking the
C-terminal TMD8, whereas addition of complex polysialo-gangliosides does not alter the interaction.
HCA displays the highest binding affinity to hSV2C and rSV2C, but much weaker affinity to rSV2A
and B. Accordingly, SV2-LD4 peptides fused to the BoNT/A C-terminus drastically reduced the
potency of BoNT/A at the neuromuscular junction. A KD of 200 nM was determined for full-length
BoNT/A binding to GST-rSV2C-LD4 in pull down experiments which agrees well with the KD of
550 nM determined for HCA to GST-rSV2C-LD4 by surface plasmon resonance (SPR) measurements.
The F563 in hSV2C-LD4 significantly enhanced BoNT/A binding to hSV2C-LD4 vs. rSV2C-LD4
displaying a leucine instead. Circular dichroism (CD) spectroscopy revealed that the quadrilateral
helix of SV2C-LD4 pre-exists in solution prior to BoNT/A binding. In comparison to the BoNT/B–Syt
interaction, the recognition of SV2 by BoNT/A follows a different mechanism. In summary, these data
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further deepen the understanding of the BoNT/A-SV2 receptor interaction and provide a basis for
developing peptidic BoNT/A inhibitors as botulism countermeasures or high affinity peptides for










putative N‐glycosylation sites  in SV2C‐LD4  (amino acid  (AA) 454–579) are depicted as “Y”,  those 
three strictly conserved among SV2A‐C in black. The ten residues displaying side chain interactions 
between human (h) SV2C and HCA are indicated in single letter code, the four AA differing to rSV2C 
are  listed additionally. F563 of hSV2C reported  to mediate an  important cation–π  interaction with 
R1156 of BoNT/A [29] is highlighted in orange (B) hSV2C 456–574 (visible only AA 473–565) bound 
Figure 1. (A) Membrane topology of rat synaptic vesicle glycoprotein 2 isoform C (SV2C). Residues
identical in rSV2A-C are col red in black, those only conserved in rSV2A or rSV2B in grey. The five
putative N-glycosylation sites in SV2C-LD4 (amino acid (AA) 454–579) are depicted as “Y”, those
three strictly conserved among SV2A-C in black. The ten residues displaying side chain interactions
between human (h) SV2C and HCA are indicated in single letter code, the four AA differing to rSV2C
are listed additionally. F563 of hSV2C reported to mediate an important cation–π interaction with
R1156 of BoNT/A [29] is highlighted in orange (B) hSV2C 456–574 (visible only AA 473–565) bound to
BoNT/A HC (4JRA.pdb). Surface of HCA is shown in blue, the peptide backbone of hSV2C as green
ribbon. The ten hSV2C residues displaying side chain interactions with HCA are depicted as grey
sticks, of them F563 is highlighted in orange.
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2. Results
2.1. Effect of Gangliosides and SV2C Transmembrane Domain on Binding of BoNT/A to GST-rSV2C
The neuronal uptake of BoNT/A, B, E and G occurs via a double receptor binding mechanism
employing a complex polysialo-ganglioside as well as a synaptic vesicle protein receptor [11,14,30,35].
Accordingly, for BoNT/B and G it was demonstrated also in vitro that the presence of gangliosides
synergistically increases the affinity to Syt-I and Syt-II incorporated into detergent micelles via their
TMD. However, in the absence of gangliosides the affinity of Syt-I and Syt-II with TMD to BoNT/B
and G decreases below that of Syt-I and Syt-II without TMD, presumably due to steric constraints at
the micelle surface [11]. Similar analyses for SV2, the corresponding protein receptor for BoNT/A
and E, are lacking. The LD4 of SV2 is presented by TMD7 and TMD8 into the vesicle lumen
(Figure 1A). To analyze whether the BoNT/A–SV2C interaction behaves similarly, we performed GST
pull down experiments employing GST-rSV2C 454–579 (LD4) and GST-rSV2C 454–603 (LD4 + TMD8)
in the presence and absence of complex polysialo gangliosides and H6tBoNTA as ligand (Figure 2).
Analogous to the BoNT/B–Syt interaction [11], presence of the TMD8 in GST-rSV2C 454–603 decreases
the binding of H6tBoNTA by 34% compared to GST-rSV2C 454–579 and also the presence of
gangliosides does not alter the binding of BoNT/A to GST-rSV2C 454–579 lacking the TMD. However,
in contrast to BoNT/B–Syt interaction [11], gangliosides and SV2C plus TMD do not act synergistically
on binding of BoNT/A. Here, the binding of BoNT/A to GST-rSV2C 454–603 plus gangliosides is even
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Figure 2. Glutathion-S-transferase (GST) pull down experiments employing GST-rSV2C 454–579
(luminal domain 4, LD4) and GST-rSV2C 454–603 (LD4 + transmembrane domain 8,TMD8) and GST
(each 75 pmol), in the presence and absence of complex ganglioside mixture (125 µg) and single-chain
H6tBoNTA wt (250 nM) as ligand in 100 mM Tris-HCl pH 8.0, 150 mM NaCl and 0.5% Triton X-100.
Sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) analysis of pellet samples
of a representative experiment (left). Protein bands were stained by Coomassie blue and bands of
H6tB NTA, GS -rSV2C and GST (indicated by arrow) were densitometrically quantified. Mean ˘ SD
of H6tBoNTA absolute binding in mo % to GST-rSV2C after subtraction of background binding to
GST-GT matrix of n = 3 technical replicates is shown (right).
2.2. Binding of HCA to rSV2A-C Isoforms and hSV2C
Full-length rSV2C displays 62.3% and 59.7% AA sequence identity with rSV2A and rSV2B,
respectively, whereas its LD4 (AA 454–579) is only 47.6% and 44.0% identical to rSV2A 468–594 and
rSV2B 411–535, respectively (Figure 1A). The latter two LD4s are 54.4% identical to each other. Overall,
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only 44 of 125 residues in LD4 are identical in all three isoforms. Such diversity was suspected to
influence the recognition by BoNT/A. Using GST-rSV2A 468–594, GST-rSV2B 413–535, GST-rSV2C
454–579 and GST-hSV2C 455–579 in pull down experiments, we determined the relative binding
strength of the isolated cell binding domain HCA (Figure 3). HCA displayed with 5.5 ˘ 1.6 mol % the
lowest binding to rSV2B closely followed with 7.4 ˘ 0.7 mol % to rSV2A. rSV2C binds 39.2 ˘ 5.9 mol %
of HCA which is approximately 5- and 7-fold more than rSV2A and rSV2B, respectively. Since eleven
residues of rSV2C LD4 differ in hSV2C, the latter was also analyzed for binding to HCA. GST-hSV2C
455–579 displayed a 10% increased binding compared to GST-rSV2C 454–579 (Figure 3), however,
an unpaired t-test revealed a p-value of 0.1319 which indicates that for 500 nM HCA ligand the mean
of GST-hSV2C 455–579 is not significantly higher than of GST-rSV2C 454–579.
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Figure 3. GST pull down experiments employing GST-rSV2 468–594, GST-rSV2B 413–535, GST-rSV2C
454–579 and GST-hSV2C 455–579 (each 1 0 pmol) without complex gangliosi es and HCAS wt (500 nM)
as ligand in 20 mM Tris-HCl pH 7.4, 80 mM NaCl, 0.5% Triton X-100. Mean ˘ SD of HCAS absolute
binding in mol % to rSV2A (n = 3), rSV2B (n = 3), rSV2C (n = 14) and hSV2C (n = 9) after subtraction of
background binding to GST-GT matrix is shown.
2.3. F563L Mutation Decreases Binding of hSV2C to BoNT/A
The binding constant KD of full-length BoNT/A to rSV2C has not yet been determined. For that
purpose, we performed a pull down assay with immobilized GST-rSV2C 454–579 (75 pmol) and
increasing concentrations of single chain H6tBoNTA (31 nM–1 µM). Fitting a function to the saturation
binding curve as well as a Scatchard plot analysis revealed a KD « 200 nM for H6tBoNTA (Figure 4A),
which agrees well with the KD of 260 nM determined for HCA binding to hSV2C 456–574 by
fluorescence anisotropy experiments [29].
To verify whether the binding of full-length BoNT/A to hSV2C differs compared to rSV2C, tag-free
fully activated BoNT/A [36] was tested as ligand in varying concentrations (15–7600 nM) in pull down
assays (Figure 4B). Indeed, the affinity of BoNT/A towards hSV2C LD4 is significantly higher (p = 0.036)
than to rSV2C LD4. As indicated in Figure 1A, four of the ten SV2C residues displaying prominent side
chain interactions with BoNT/A differ between rat and human SV2C. Non-conservative substitutions
are found at positions 558 (rat: Q/human: K) and 563 (rat: L/human: F). F563 of hSV2C has been
reported to mediate an important cation–π interaction with R1156 of BoNT/A [29] which cannot
be established by the aliphatic leucine present in rSV2C. This raised the question of whether F563
exclusively caused the difference in affinity observed between rat and human SV2C (Figure 4B).
To probe its role we generated the mutant GST-rSV2C 455–579 F563L and compared its binding to
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BoNT/A with the two wild-type GST-SV2C constructs (Figure 4B/C). As anticipated, the binding of
BoNT/A to GST-hSV2C 455–579 F563L is clearly decreased compared to its wild-type. Unexpectedly,
the binding even falls below the one observed towards GST-rSV2C 454–579, suggesting that the other
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termini  of  hSV2C‐LD4,  respectively,  yielding  H6hSV2C6xHN  and  as  a  control  hSV2C6xHN 
comprising only the C‐terminal 6xHN‐tag. Interestingly, placement of the small affinity tag to the C‐
Figure 4. (A) Determination of binding constant KD of single chain H6tBoNTA to rSV2C 454–579:
GST-rSV2C 454–579 (75 pmol) was immobilized and 31 nM–1 µM single-chain H6tBoNTA in 100 mM
Tris-HCl pH 7.4, 150 mM NaCl, 0.5% Triton X-100 were added as ligand (n = 2). Bound H6tBoNTA
was quantified by SDS-PAGE and densitometry upon Coomassie blue staining. (B) Comparison
of SV2C-LD4 fused to different affinity tags in pull down experiments. GST-rSV2C 454–579,
GST-hSV2C 455–579, GST-hSV2C 455–579 F563L, H6hSV2C6xHN and hSV2C6xHN (each 75 pmol)
were immobilized and tag-free di-chain BoNTA in PBS, 0.5% Triton X-100, pH 7.4 was added in ten
different concentrations (15–7600 nM) as ligand (n = 3); (C) Representative SDS-PAGE analysis of a
GST pull down experiment employing immobilized GST-hSV2C 455–579 F563L and tag-free di-chain
BoNTA (15–4000 nM).
The SV2-LD4 is presented by TMD7 and TMD8 to the SV surface. To mimic such presentation, we
fused two short peptides able to bind to IMAC matrix containing Ni2+ or Co2+ to the N- and C-termini
of hSV2C-LD4, respectively, yielding H6hSV2C6xHN and as a control hSV2C6xHN comprising only
the C-terminal 6xHN-tag. Interestingly, placement of the small affinity tag to the C-terminus mimicking
the presentation of the LD4 via its TMD8 increased binding of BoNT/A to hSV2C6xHN compared to
GST-hSV2C comprising a much larger N-terminal tag and a freely floating SV2C C-terminus. However,
addition of the H6-tag to the N-terminus and hence presenting SV2C-LD4 fixed on both termini like in
full-length SV2C on the SV surface did not alter the binding to BoNT/A (Figure 4B).
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2.4. Binding Affinity and Kinetics of HCA towards Immobilized GST-hSV2C 454–579
To further support our findings, we determined the binding kinetics and affinity of HCA towards
immobilized GST-rSV2C 454–579, GST-hSV2C 455–579 and GST-hSV2C 455–579 F563L mutant,
respectively, in comparison to the established interaction of HCB with GST–Syt-II 1–61 by SPR
measurements (Figure 5 and Table 1). For this purpose, polyclonal rabbit anti-GST antibodies were
covalently coupled to the sensor to specifically capture the GST-SV2C fusion proteins and GST as
control. Such an experimental approach allows for uniform presentation of the interacting peptide
with maximum degree of freedom. The measured binding responses (∆RU; red lines) were overlaid
with fits of a 1:1 Langmuir interaction (black lines; Figure 5) to yield association rate ka and dissociation
rate kd to calculate KD Kinetics (Table 1). As a test for consistency, KD Steady-state values were additionally
determined by fitting a steady-state affinity model to ∆RU values at equilibrium (Figure 5 and Table 1).
For measurements of GST-rSV2C at pH 7.3 (B) and GST-hSV2C at pH 5.0 (D), kinetic evaluation had
to be omitted due to heterogeneity in the binding curves or weak binding responses. E.g., rSV2C
showed a much higher tendency to aggregate during experimental analysis, presumably by exposing
hydrophobic amino acid patches which hampered the measurements due to incomplete regeneration
despite inclusion of an additional regeneration step with 10 mM NaOH. Additionally, some degree
of heterogeneity was observed for the interaction during SPR-measurement. A possible explanation
could be that the β-sheet tertiary structure is less stable in rat than in human SV2C, making rSV2C
more prone to aggregation due to exposed hydrophobic interactions. However, for rSV2C a reliable
KD Steady-state value could also be determined.
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Figure 5. SPR-sensorgrams of the interaction of recombinant HCB with: GST–rSyt-II 1–61 (A);
recombinant HCA with GST-rSV2C 454–579 (B); GST-hSV2C 455–579 (C); GST-hSV2C 455–579 at
pH 5.0 (D); or GST-hSV2C 455–579 F563L (E) (Inserts: Fits for determination of steady-state affinity).
The measured double referenced binding responses (∆RU; red lines) are overlaid with fits of a 1:1
Langmuir interaction (black lines). For measurements of GST-rSV2C at pH 7.3 (B) and GST-hSV2C
at pH 5.0 (D), kinetic evaluation was omitted due to heterogeneity in the binding curves ((B) dashed
lines: fit for 1:1 Lang uir interaction sho s clear deviations) or too low binding responses ((D) no
fit shown). HCA and HCB were injected in three-fold dilution series starting from 1200 nM down to
14.8 nM. The highest HC concentration was injected in duplicates except for GST-rSV2C 454–579 and
GST-hSV2C at pH 5.0.
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Table 1. Kinetic binding rate constants (ka and kd) and equilibrium dissociation constants (KD) for the
interaction of HCB with GST-rSyt-II and HCA with GST-SV2C variants.
Ligand pH ka [M´1s´1] kd [s´1] KD Kinetics [M] KD Steady State [M]
GST-rSyt-II 1–61 7.4 5.4 ˘ 0.3 ˆ 105 4.1 ˘ 0.2 ˆ 10´2 7.5 ˘ 0.8 ˆ 10´8 7.2 ˘ 1.2 ˆ 10´8
GST-rSV2C 454–579 7.3 n.a. n.a. n.a. 5.1 ˘ 0.3 ˆ 10´7
GST-hSV2C 455–579 7.3 3.1 ˘ 0.5 ˆ 105 1.2 ˘ 0.1 ˆ 10´1 3.9 ˘ 0.5 ˆ 10´7 4.0 ˘ 0.6 ˆ 10´7
GST-hSV2C 455–579 5.0 n.a. n.a. n.a. >1.2 ˆ 10´6
GST-hSV2C 455–579 F563L 7.3 1.9 ˘ 0.1 ˆ 105 1.3 ˘ 0.1 ˆ 10´1 6.8 ˘ 0.1 ˆ 10´7 6.6 ˘ 0.3 ˆ 10´7
Shown are mean ˘ SD of n = 2 technical replicates; n.a. = not applicable.
Overall, the observed interactions were characterized by rapid binding and fast dissociation and
calculated KD Kinetics were consistent with KD Steady-state values. rSyt-II displayed a higher affinity to
HCB than hSV2C to HCA due to a three-fold slower dissociation rate. In line with results of pull
down assays (Figure 3), hSV2C showed slightly higher binding affinity to HCA than rSV2C albeit
not statistically significant (n = 2; t-test: p = 0.16). Lowering the pH to values being measured in
acidifying small synaptic vesicles [37] the KD increases at least an order of magnitude. The lowered
affinity of HCA towards the F563L mutant observed in the pull down assay could be confirmed by
the SPR measurements. The affinity of HCA towards the GST-hSV2C F563L mutant was statistically
significantly (n = 2; t-test: p = 0.0143) reduced by a factor of 1.8 as compared to GST-hSV2C wild-type.
However, the effect was not as pronounced as in the pull down assay although one has to keep in
mind that for SPR measurements HCA instead of full-length BoNT/A was used.
2.5. Intramolecular Blockade of SV2 Binding Site in BoNT/A
Analogous to an earlier approach in which the Syt-II peptide fused to BoNT/B intramolecularly
occupied its own binding site thereby reducing the BoNT/B potency >10-fold [32], various SV2
peptides including an 11-mer linker (L11) were fused to the C-terminus of BoNT/A to block the
SV2 binding site. The BoNT/A–SV2 fusion proteins of up to 165 kDa were successfully generated
(Figure A1). The biological activity of these fusion proteins was determined by the mouse phrenic
nerve (MPN) hemidiaphragm assay [36,38].
Fusion of the complete rSV2C-LD4 reduced the biological activity of BoNT/A 100-fold (Figure 6).
A further 10-fold inhibition was observed upon introduction of an 11-mer linker (L11) between BoNT/A
and rSV2C 454–579 supposedly providing more flexibility to the SV2C peptide to orient correctly
on the BoNT/A surface. In contrast, N-terminal truncations of the LD4 beyond residue 473 in the
presence of the linker L11 were as potent as the BoNTA-rSV2C 454–579 lacking L11. The se truncations
shortened the flexible linker 454–472 in SV2C and abridged the quadrilateral helix N-terminally, which
might reduce its overall stability or conformation. Replacing rSV2C-LD4 by hSV2C-LD4 yielded
similar inhibition which is in accordance with the observed binding affinity of the corresponding GST
fusion proteins to HCA (Figure 3). Analogously, the fused rSV2A-LD4 blocked BoNT/A potency less
efficiently whereas rSV2B-LD4 exhibited surprisingly similar potency as rSV2C-LD4 (Figure 6).

















Figure 6. The potency of full-length BoNT/A C-terminally fused to an 11-mer linker peptide (L11) and
to on of rSV2A 468–594, rSV2B 413–535, hSV2C 454–579 or different rSV2C peptides (rSV2C 454–579
also without L11) as determined in the MPN hemidiaphragm assay and compared to scBoNTAS
wild-type. Shown is the mean ˘ SD of n = 3–5 technical replicates.
2.6. Secondary Structure Analyses of Free and Bound hSV2C Peptide
The luminal domain of Syt-II is unstructured in solution and only upon binding to HCB
residues E44-K60 become structured, with residues F47-I58 forming an α-helix [32]. To determine
the solution structure of SV2C-LD4 we isolated the hSV2C 455–579 peptide by thrombin digest of
GST-hSV2C 455–579 and subsequent gelfiltration (Figure 7A). In contrast to rSV2C 454–579, which
readily precipitates upon release from GST, the hSV2C 455–579 peptide is sol ble, monomeric and
stable in physiologic l buffer. We performed CD measurements of free hSV2C peptide and HCAS,
respectively, as well as of a 1:1 mixture of hSV2C peptide and HCAS to compare secondary structure of
hSV2C in bound and free state (Figure 7B).
Isolated hSV2C displays a spectrum rich in β-sheet (Figure 7B, red trace) and typical for proteins
folded as quadrilateral helices like Mycobacterium tuberculosis pentapeptide repeat protein (PRP)
MtMfpA [39,40] or luminal Rfr32, a 167-residue PRP from diurnal cyanobacterium Cyanothece species
51142 [41–43]. Secondary structure estimation according to Reed and Reed [44] for the hSV2C peptide
revealed 38% β-sheets, 4% turns and 58% random coil without any α-helix which agrees well with the
solved crystal structure of bound hSV2C [29]. Addition of 8 M urea completely abolished its molar
ellipticity signal. Isolated HCA yields a spectrum of a protein comprising mainly β-sheets and is
similar to spectra previously determined for HCB and HCG [11]. Hereafter, HCAS and hSV2C peptide
were mixed in a 1:1 stoichiometry. The immediate measurement yielded a spectrum dominated by
β-sheet content (Figure 7B, black trace). A subsequent incubation for 30 min at 4 ˝C and a re-scan of
the mixture showed an unaltered spectrum. To check whether secondary structure content, e.g., of
the hSV2C peptide, was altered upon presence of HCAS, the spectra of free hSV2C and HCAS were
arithmetically added (Figure 7B, grey trace). The summarized spectrum was virtually identical to that
of the HCAS-hSV2C mixture (black race) indicating that no alteration in secondary structure content
occurred in HCA and hSV2C, respectively. Conversely, the CD signal of free hSV2C or HCAS was
subtracted from the spectrum of the HCAS-hSV2C mixture. In both cases, the resulting difference
spectrum was highly similar to that measured of the respective isolated protein. In conclusion, hSV2C
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seems to fold already in solution as quadrilateral helix and binding to HCA does not induce a change
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Figure 7. CD secondary structure analyses of free and bound hSV2C peptide. (A) GST-hSV2C 455–579
was quantitatively digested with thrombin and the released hSV2C peptide (15.6 kDa) was isolated
by gelfiltration (fractions 11a–15). (B) Far-UV CD spectra of free hSV2C peptide (5 µM; red trace),
free HCAS (8 µM, dark blue) and a 1:1 mixture of hSV2C-HCAS (5 µM; black). Arithmetic addition
of spectra of free hSV2C (red) and free HCAS (dark blue) yields a spectrum (grey) similar to that
of the hSV2C-HCAS mixture (black). Accordingly, subtraction of CD signal of either hSV2C (light
blue) or HCAS (orange) from that of the hSV2C-HCAS mixture yielded spectra similar to that of the
corresponding free protein.
3. Discussion
The recognition of SV proteins as receptors by botulinum neurotoxins is a highly critical step in
their intoxication pathway. Following the low affinity accumulation of BoNT by the abundant complex
polysialo-gangliosides on the neuronal surface only a high affinity interaction with the SV protein
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provides sufficient specificity and avidity to enable efficient uptake of the BoNT into the lumen of
small SV.
3.1. Unlike for BoNT/B–Syt-II, the Dual-Receptor Binding of BoNT/A–SV2C Cannot Be Reconstituted
in Solution
Using a similar experimental setup as previously used for BoNT/B–Syt-II [11] we analyzed
whether SV2C membrane integration and presence of complex polysialo-gangliosides contributes
to BoNT/A affinity in vitro. Although we experimentally proved the double receptor recognition of
BoNT/A recently [30], we observed neither a synergistic nor an additive effect on BoNT/A binding
to SV2C in the presence of gangliosides. We speculate that the single TMD8 on the C-terminus
important for micelle/membrane integration might fold back and binds to hydrophobic patches
on the quadrilateral helix thereby blocking the surface used by BoNT/A. Alternatively, the TMD8
fails to orient the LD4 as required for BoNT/A to simultaneously bind SV2C and gangliosides.
Obviously, the steric requirements for full-length BoNT/A to approach membrane juxtaposed SV2
LD4 are by far more demanding than for HCA which might explain the observation that isolated
HCA displays increased binding to GST-rSV2C 454–603 in the presence of gangliosides compared to
GST-rSV2C 454–579 lacking TMD8 [23]. Hence, the dual-receptor binding of BoNT/A–SV2C cannot be
reconstituted in solution as for BoNT/B–Syt-II. Furthermore, mimicking the membrane presentation
of SV2C-LD4 by fixing the hSV2C peptide via two affinity peptides to an IMAC matrix did not alter
the binding of BoNT/A. Here, a simultaneous binding also to gangliosides could not be analyzed due
to the lack of TMD8 in the H6hSV2C6xHN and hSV2C6xHN constructs.
3.2. Sequence Diversity in the Interacting Residues and Destabilization of Quadrilateral Helix Might Cause
Lower Binding of BoNT/A to SV2A and SV2B as Compared to SV2C
The SV2A-C isoforms display a high homology and share ~60% AA sequence identity, but only 44
of 125 residues in LD4 are identical in all three isoforms. One can expect that this moderate homology
in LD4 will influence physiological function and more importantly, the recognition by BoNT/A and E.
Indeed, BoNT/E is only able to interact with SV2A and SV2B but not SV2C [24,35] which is most likely
due to differences in AA sequence. Here, we demonstrate that rSV2A and rSV2B bind HCA 5–7-fold
less than rSV2C, but determination of a binding constant KD by pull down as well as SPR assays
for the interaction of BoNT/A and HCA vs. SV2A and SV2B, respectively, failed because of too low
affinity. A similar qualitative order of binding affinity was previously observed [22]. Despite the major
backbone–backbone interactions visible in the hSV2C-HCA complex, ten side chain residues mediate
sequence specific interactions. Of these ten residues eight are dissimilar in rSV2A and nine in rSV2B
while four of them also differ between rSV2A and rSV2B. Such diversity partially explains the low
affinity binding observed for BoNT/A to SV2A and SV2B and the absence of BoNT/E binding to SV2C.
Analysis of the phenylalanine pentapeptide repeats causing the quadrilateral helix folding of LD4
revealed two sites each in SV2A and SV2B with a mispositioned or even lacking phenylalanine, which
might impair stability or correct folding of the quadrilateral helix. Repositioning and/or replenishing
the lacking phenylalanine led to increased protein solubility of the SV2A and SV2B mutants as well
as increased their binding to BoNT/A [45]. Hence, differences in residues of the pentapeptide repeat
folding the quadrilateral helix as well as of those ten residues interacting via their side chains with
BoNT are supposed to be responsible for the low level binding of SV2A and SV2B to BoNT/A.
3.3. On a Species Level, Beneficial Mutations Seem to Compensate Loss of Binding Strength Caused by
Deteriorating Mutations
The differences in affinity observed for hSV2C vs. rSV2C must be ascribed to the four residues
in LD4 interacting with BoNT/A, but differing between human and rat SV2C. Of the two residues
with non-conservative substitutions (Q558K, L563F), F563 of hSV2C has been reported to mediate an
important cation–π-stacking interaction with R1156 of BoNT/A [29], which cannot be established by
Toxins 2016, 8, 154 12 of 20
the aliphatic L563 in rSV2C. Indeed, mutant hSV2VC F563L displays clearly reduced affinity in pull
down assays (Figure 4B) and moderately reduced affinity in SPR analyses (Table 1) to BoNT/A or HCA,
respectively. Interestingly, aromatic residues at position 563 are only present in human, chimpanzee,
chicken, dog, zebrafish and pufferfish SV2C, but a correlation with BoNT/A potency in those species
comprising a non-aromatic AA in SV2C has not been exhibited yet.
3.4. SV2 Peptides Fused to BoNT/A Display a Higher Inhibitory Potency as Syt-II Petides towards BoNT/B
Complementary to the affinity determined by pull down assays, an intramolecular inhibition
of protein receptor binding was conducted to evaluate the binding strength of SV2 peptides to
BoNT/A. Previously, a BoNT/B–Syt-II fusion protein displayed >10-fold reduction in potency due to
autoinhibition [32]. Fusing rSV2C directly to the C-terminus of BoNT/A decreased its potency even
100-fold. This 10-fold higher effect may partially be attributed to the different location of Syt and SV2
binding sites in HCB and HCA, respectively. The SV2 site comprises inter alia the last five BoNT/A
residues and fusion of any larger peptide might disturb SV2 binding. However, insertion of a 11-mer
linker between the C-terminus of BoNT/A and the SV2C provides more flexibility of the latter to
orient into its binding site and resulted in an additional 10-fold reduction of potency. Accordingly,
N-terminal truncation of the rSV2C and replacement by rSV2A reversed potency indicating specific
intramolecular inhibition of BoNT/A by SV2 peptides according to their binding site affinity.
3.5. The Interaction between HcA and SV2C is Highly Transient, Characterized by Rapid Binding
and Unbinding
First SPR data on HCB–rSyt-II interaction displayed a fast association rate ka despite preceding
folding of the Syt-LD α-helix and an intermediate dissociation rate kd yielding a binding constant of
75 nM which agrees well with the KD of 34 nM [32] and 140 nM [14] determined by isothermal titration
calorimetry (ITC). Although the SV2C quadrilateral helix pre-exists, HCA binds to hSV2C as quick as
HCB to Syt-II, but its dissociation rate is 3-fold faster presumably due to the weaker backbone–backbone
interactions. The refore, binding constants of 500 nM for GST-rSV2C-HCA in SPR measurements and
200 nM for GST-rSV2C-BoNT/A in pull down assay were calculated. Hence different methods using
different ligands like HCA or full-length BoNT/A (which could not be measured in SPR for safety
reasons) largely arrive at the same overall binding affinity. The slightly lower KD of ~400 nM for
the interaction between GST-hSV2C 454–579 wild-type and HCA in SPR is in good agreement with
previous affinity data of 260 nM determined for hSV2C 456–574 peptide by fluorescence anisotropy
experiments [29] taking into account that different SV2C constructs and methods were used for
measurements. However, the binding kinetics determined in this work are in strong contrast to
binding kinetics of HCA towards a hSV2C 529–579 peptide measured in another work [46]. While the
overall affinity of hSV2C 529–579 was only moderately stronger (105 nM), the association rate constant
(ka = 2.3 ˆ 103 M´1s´1) and the dissociation rate constant (kd = 2.5 ˆ 10´4 s´1) were significantly
slower by a factor of 135 and 480, respectively. Jacky et al. [46] covalently immobilized HCA by
amine coupling to a CM5 sensor chip yielding a random presentation. In contrast, we captured the
GST-SV2C peptides by anti-GST antibodies, where the SV2C is uniformly oriented to the solvent.
Furthermore, Jacky et al. [46] injected the synthetic hSV2C 529–579 peptide dissolved in DMSO over
the sensor surface. The requirement of using DMSO as solvent indicates that the hydrophobic core of
the quadrilateral β-sheet helix [29] might be solvent exposed due to misfolding [47] which renders
the molecule rather “sticky”. This would explain the pronounced reduction in both association and
dissociation rate constants, hereby falsifying the interaction. On the contrary, we used a directed
capture approach for capturing GST-SV2C 454–579 and injected HCA in physiological buffer over the
sensor surface, hereby mirroring the natural presentation of the SV2C receptor on the surface of the
presynaptic membrane [22,23] without potential disturbances by covalent immobilization of HCA and
denaturation of hSV2C by solvent [47]. Finally, the mandatory overlay of the curve fitting employing
the 1:1 kinetic-binding model (A + BØAB) with the raw data is missing in Jacky et al. [46] and disables
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the reader to evaluate the quality of curve fitting. Simulating the HCA-hSV2C 529–579 interaction by
the BIA simulation software 2.1 employing the 1:1 kinetic-binding model (A + BØAB), the above cited
ka, kd and KD and five hSV2C peptide concentrations surprisingly yields curves (Figure A2) which
do not fit with the sensorgrams given in Figure 3A of Jacky et al. [46] and questions the validity of
their SPR study. Taking into account this finding and considering the influence of electrostatic charge
interactions on the binding between HCA and hSV2C [29], which are known to enhance association
rate constants [48], let us conclude that the more rapid association and dissociation rate constants
reported here describe the BoNT/A–SV2C interaction more accurately.
3.6. A Preformed Structure in Solution and pH-Dependent Binding Distinguish SV2C and Syt-II
The increase of the KD at pH 5.0 which reflects the situation of BoNT/A in acidifying small SV
is in contrast to the BoNT/B–Syt-II interaction which is pH-independent [32]. Due to the differently
localized protein receptor binding sites it might be necessary for BoNT/A to dissociate from SV2C to
be able to reorient prior to membrane insertion as prerequisite for pore formation and LC translocation.
Along that line, it was shown that HC mediates pH-dependent translocation [49].
In contrast to Syt-I and -II which change their unstructured luminal domain upon BoNT binding
into an α-helix which exclusively forms side chain interactions with BoNT/B and G [50], our CD
data suggests that isolated SV2 LD4 exists as preformed quadrilateral β-sheet right handed helix as
observed in the X-ray structure [29]. Fixation of this stable helix by two transmembrane anchors to
the vesicle lumen then allows for the establishment of backbone–backbone interactions within a small
interface of HCA at a site distinct to the Syt site in BoNT/B and G.
4. Conclusions
Here, we have further characterized the BoNT/A–SV2 protein–protein interaction. BoNT/A displays
the highest binding affinity to hSV2C and rSV2C, but much weaker affinity to rSV2A and B. It binds
preferable to rSV2C-LD4 lacking the C-terminal TMD8 independent of complex polysialo-gangliosides
which is in sharp contrast to the BoNT/B–Syt-II receptor interaction. Accordingly, SV2-LD4 peptides
fused to the BoNT/A C-terminus drastically reduced the potency of BoNT/A at the neuromuscular
junction. Fast association and dissociation of BoNT/A to SV2C-LD4 pre-existing as quadrilateral
helix yields binding constants of 200–500 nM. The F563 in hSV2C-LD4 enhances BoNT/A binding to
hSV2C-LD4 vs. rSV2C-LD4 displaying a leucine instead, whereas acidic pH measured in SV drastically
weakens the BoNT/A–SV2C interaction. In conclusion, the mechanism and way of receptor recognition
of BoNT/A clearly diverges from BoNT/B which might be attributable to the different location of the
protein receptor binding sites in BoNT/A and B. Our data further deepen the molecular understanding
of the BoNT/A–SV2 receptor interaction and supports the generation of novel SV2-based peptides as
inhibitors to counteract deliberate release of BoNT/A and E and as high affinity agents in innovative
detection systems to capture functional BoNT/A variants e.g., from complex matrices to prevent and
diagnose botulism.
5. Materials and Methods
5.1. Plasmid Construction
Plasmids encoding the HC-fragment of BoNT/A fused to a C-terminal Streptag (HCAS), single
chain full-length BoNT/A equipped with an N-terminal, thrombin-cleavable His6tag (H6tBoNTA),
full-length BoNT/A with thrombin-cleavable tags (BoNTA) as well as GST fusion proteins of rSV2A
468–594, rSV2B 413–535, rSV2C 454–579 and rSV2C 454–603 were described previously [9,23,30,36].
The plasmid pGEXhSV2C 455–579 encoding GST-hSV2C 455–579 was generated by cloning
the synthetic E. coli codon usage optimized DNA sequence encoding hSV2C 455–579 (Geneart,
Regensburg, Germany) into a pGEX-4T3 vector cut with BamH I/Xma I. The mutation F563L was
inserted into pGEXhSV2C 455–579 by PCR applying the GeneTailor™ site-directed mutagenesis
Toxins 2016, 8, 154 14 of 20
system (Life Technologies, Darmstadt, Germany) and suitable primers (Eurofins, Ebersberg, Germany).
pGEXhSV2C-6xHN 455–579 was generated by inserting a DNA fragment encoding a 6xHN tag into
pGEXhSV2C 455–579 via Xma I/Xho I sites. The plasmid encoding pGEXH6hSV2C-6xHN 455–579
was generated from pGEXhSV2C-6xHN 455–579 by inserting a DNA-fragment encoding a H6-tag
employing the 51 BamH I site.
Expression vectors encoding variants of BoNTA-SV2-S fusion proteins were generated by opening
pBoNTAS wt at the bont/A 31 end using the unique Sma I site [9] and inserting Sma I digested PCR
products which contain an additional EcoR V site at the 51 end and were amplified from pGEXrSV2A
468–594, pGEXrSV2B 413–535, pGEXrSV2C 454–579 and pGEXhSV2C 455–579. The expression vectors
encoding the BoNTA-L11-SV2-S fusion proteins were generated by linearizing the corresponding
pBoNTA-SV2-S plasmids at the unique EcoR V site and inserting a synthetic blunt end DNA fragment
encoding the linker L11 (GGSGSSGSSGA).
Nucleotide sequences of all newly generated constructs were verified by DNA sequencing
(GATC Biotech, Konstanz, Germany).
5.2. Expression and Purification of Recombinant Proteins
The generation of HCAS, scBoNTAS, single-chain H6tBoNTA and activated full-length BoNTA were
described previously [9,30,36]. Expression and purification of the fusion proteins scBoNTA-rSV2C-S,
scBoNTA-L11-rSV2C-S and variants thereof was conducted analogously to that of scBoNTAS wild-type
under biosafety level 2 containment (project number GAA A/Z 40654/3/123) [9].
GST fusion proteins (GST-rSV2A 468–594, GST-rSV2B 413–535, GST-rSV2C 454–579, GST-rSV2C
454–603 were purified as described earlier [23]. The novel GST-hSV2C 455–579, GST-hSV2C 455–579
F563L, GST-hSV2C-6xHN 455–579 and GST-H6hSV2C-6xHN 455–579 were produced analogously.
GST fusion proteins eluted by glutathione were dialyzed against PBS, pH 7.4, two times with,
and two times without β-mercaptoethanol. GST-hSV2C-6xHN 455–579 and GST-H6hSV2C-6xHN
455–579 stayed bound to glutathione-sepharose-4B matrix (GE Healthcare, Freiburg, Germany) while
GST-hSV2C 455–579 was eluted and were treated for 16 h shaking at room temperature with 0.01 U
bovine thrombin (Sigma-Aldrich Chemie GmbH, Steinheim, Germany) per µg protein in 0.1 M Tris-HCl
pH 8.0, 150 mM NaCl supplemented with 1 mM CaCl2 to cleave off the SV2C peptide from the GST-tag.
The released (H6)hSV2C6xHN-peptides were isolated from the supernatant using Co2+-Talon matrix
(Takara Bio Europe S.A.S., Saint-Germain-en-Laye, France) and eluted with 50 mM Tris-HCl, pH 8.0,
150 mM NaCl, 250 mM imidazole. The released hSV2C-peptide was purified from the supernatant
by gelfiltration in PBS, pH 7.4. Desired fractions were pooled, dialyzed against PBS pH 7.4, frozen in
liquid nitrogen and kept at ´70 ˝C.
Protein concentrations were determined subsequent to SDS-PAGE and Coomassie blue staining
by using a LAS-3000 imaging system (FUJIFILM Europe GmbH, Düsseldorf, Germany), the AIDA 3.51
software (Raytest, Straubenhardt, Germany) and BSA (100–1600 ng) as reference protein.
5.3. Pull Down Assay
The GST pull down assays were similarly performed as previously described [30] with the
addition of 125 µg ganglioside mixture (Matreya, State College, PA, USA) in selected experiments
as indicated.
Briefly, GST, GST fusion proteins and 6xHN-tagged fusion proteins (75 or 150 pmol each) were
immobilized to 10 µL glutathione-sepharose-4B matrix (Qiagen, Hilden, Germany) or 5 µL Co2+-Talon
matrix (Takara Bio Europe S.A.S., Saint-Germain-en-Laye, France), respectively, and subsequently
incubated for 2 h at 4 ˝C with HCAS, single chain H6tBoNTA or di-chain BoNTA in a total volume
of 100–200 µL in binding buffer as stated in the respective figure legends. Beads were collected by
centrifugation and washed two times each with the corresponding binding buffer. Washed pellet
fractions were incubated at 37 ˝C for 20 min in SDS sample buffer and analyzed by 10% SDS-PAGE.
Protein bands were detected by Coomassie blue staining and subsequently quantified by densitometry
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using the software TINA (version 2.09f, Raytest, Straubenhardt, Germany). Unspecific binding of
ligand to immobilized GST or free Co2+-Talon matrix was subtracted from the specific binding signal
of HCA or BoNTA to SV2. KD values and statistics were calculated with GraphPadPrism (version 4.03
January 2005, GraphPad Software Inc., La Jolla, CA, USA).
5.4. Surface Plasomon Resonance Measurements (SPR)
SPR measurements to determine binding kinetics and/or affinity of recombinant HCA-fragments
towards GST-hSV2C 455–579 and GST-rSV2C 454–579 were performed using a Biacore X100 unit
(GE Healthcare, Freiburg, Germany) at 25 ˝C. PBS (pH 7.3) or 51.4 mM Na2HPO4, 24.3 mM
Citrate, 150 mM NaCl (pH 5.0) supplemented with 0.5% Triton X-100 were used as running buffer.
For GST-rSyt-II 1–61, HBS-EP+ (GE Healthcare, Freiburg, Germany) was used as running buffer.
Recombinant GST-fusion proteins were immobilized employing the GST capture kit (GE Healthcare,
Freiburg, Germany) according to the manufacturer’s recommendations. Briefly a CM5 sensor chip
was covalently coupled with rabbit anti-GST capture antibodies. For each measurement, GST-hSV2C
455–579 (wt or F563L) or GST-rSV2C 454–579 and, as a negative control, recombinant GST (both at
5 µg/mL) were captured for 30 s at a flow rate of 5 µL/min on flow cells 2 or 1, respectively, leading to
immobilization levels of approximately 200 resonance units (RUs).
For kinetic measurements, three-fold dilution series of HCA or HcB (1200, 400, 133, 44, 14.8 nM)
were injected over both flow cells for 60 or 120 s at a flow rate of 30 µL/min. Dissociation was
monitored subsequently for 120 or 300 s by running buffer injections. Between measurements, the
sensor surface was regenerated by injections of 10 mM glycine-HCl (pH 2.1) for 120 s over both flow
cells. Due to incomplete regeneration for GST-rSV2C 454–579 measurements and GST-hSV2C 455–579
(pH 5.0), an additional injection of 10 mM NaOH for 15 s at 10 µL/min was necessary to completely
remove bound HCA from the flow cells. Duplicate injections of the highest HCA concentration as well
as triplicate injections of running buffer only were included. Due to the harsh regeneration conditions
necessary during GST-rSV2C 454–579 and pH 5.0 measurements, a gradual loss of immobilization
levels was observed. The refore, the duplicate measurement of the highest HCA concentration had to
be omitted from this analysis to enable robust global fitting of binding affinities.
Kinetic association and dissociation binding rate constants (ka and kd) and the equilibrium
dissociation constant KD were determined by fitting double referenced sensorgrams [51] to a 1:1
Langmuir interaction model with RI set to 0 and Rmax set global using the Biacore evaluation software
(v2.01). KD values were additionally determined by fitting to a steady-state affinity model as a test for
consistency between kinetic and affinity analysis of the interactions.
5.5. Potency of BoNT/A–SV2 Fusion Proteins at MPN Hemidiaphragm Assay
Intramolecular inhibition of BoNT/A by fusing various SV2 peptides to the C-terminus of
scBoNTAS was determined employing the MPN assay [36,38]. In brief, the left phrenic nerve
hemidiaphragm was excised from euthanized female mice of strain RjHan:NMRI (18–25 g, Janvier
Labs, Genest Saint Isle, France), placed in an organ bath and equilibrated for 15 min in 4 mL of Earle’s
Balanced Salt Solution, pH 7.4 gassed with 95% O2 and 5% CO2. The phrenic nerve was continuously
electro-stimulated (frequency 1 Hz, 0.1 ms pulse duration, 25 mA current). Isometric contractions
(resting tension ~10 mN) were recorded with a force transducer (Scaime, Annemasse, France) and the
software VitroDat (Föhr Medical Instruments GmbH (FMI), Seeheim, Germany). Toxin was applied
in 4 mL of Earle’s Balanced Salt Solution supplemented with 0.1% BSA in concentrations to allow
50% decay of the contraction amplitude within 50 to 150 min. The times required to decrease the
amplitude by 50% (paralysis time t½ ď 180 min) for three BoNT concentrations were used to construct
the calibration curves for scBoNTAS to which a power function was fitted (y (scBoNTAS; 0.8/3/8 pM)
= 108.61x´0.355, R2 = 0.894). This power function was used to convert the paralysis times t½ determined
for BoNTA-SV2 constructs into the corresponding scBoNTAS wt concentrations and expressed as
relative biological activity of scBoNTAS wt.
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5.6. Circular Dichroism Analysis
Circular dichroism (CD) data was collected with a Jasco J-810 spectropolarimeter (JASCO
International Co. Ltd., Tokyo, Japan) in a 1 mm path length cuvette with a concentration of 5–8 µM
degassed HCA and 5 µM hSV2C in PBS pH 7.4. Spectra were recorded at 22 ˝C from 195 to 250 nm
with 100 nm/min, response of 1 s, standard sensitivity, bandwidth of 1 nm and five accumulations.
Spectra were analyzed, processed and visualized using Spectra Manager II software (version 2.06,
JASCO International Co. Ltd., Tokyo, Japan, 2007).
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HC carboxyl-terminal half of HC
HCA, HCB, HCE HC fragment of BoNT serotype A, B and E, respectively
HCN and HCC 25 kDa halves of HC
HN amino-terminal half of HC
H6 N-terminal 6x His tag
6xHN (HisAsn)6 tag
kDa kilo Dalton
L11 11-mer linker peptide
LC light chain
LD luminal domain
MPN assay mice phrenic nerve hemidiaphragm assay
MW molecular weight
PRP pentapeptide repeat protein
RU resonance unit
S C-terminal Streptag
SDS-PAGE sodium dodecylsulfate polyacrylamide gel electrophoresis
SNAP-25 synaptosomal associated protein of 25 kDa
SNARE soluble N-ethylmaleimide-sensitive factor attachment protein receptor
SPR surface plasmon resonance
SV synaptic vesicle
rSV2A-C rat synaptic vesicle glycoprotein 2 isoform A, B or C
Syt synaptotagmin
TMD transmembrane domain

































Figure A1. SDS-PAGE analysis of single chain scBoNTA–SV2 fusion proteins in comparison to scBoNTA
wild-type. Full-length scBoNTA was fused C-terminally to an 11-mer linker peptide (L11) and to one of
rSV2A 468–594, rSV2B 413–535, hSV2C 455–579 or a different rSV2C peptide (rSV2C 454–579 with and






















100 RU. (B) F r  omp rison, the measured sensorgr m was taken from Figure 3A of Jacky et al. [46]. 
Here, a mandatory overlay for the binding re ponse of the 1:1 La gmuir interaction was not shown, 
so a direct appraisal of the quality of the fit was impossible. For concentrations up to 1667 nM, an 
acceptable agreement between the simulated and reported curves can be seen. Clear deviations are 






Figure 2. Comparison of simulated an reported SPR-sensorgrams for the interaction of immobilized
HCA with a synthetic SV2C p ptide (AA 529–579) as reported by Jacky et al. [46]. (A) Using the
BIAsimulation software 2.1 (GE Healthcar ), the reported kinetic binding data (KD = 96.2 nM,
ka = 1.29 ˆ 103 M´1s´1, kd = 1.24 ˆ 10´4 s´1) was used to simulate the expected binding resp nse at
the indicated SV2C c ncentrations (61 nM to 5000 nM) assuming a axi um binding r sponse Rmax
of 100 RU. (B) For c mparison, the measured senso gram was taken from Figure 3A of Jacky et al. [46].
Here, rl for the binding response of the 1: Langmuir interaction was not shown, so a
direct appr isal of the quality of the fit was impossible. For concentrations up o 1667 nM, an acceptable
agreement betwee th simulated and reported curves can be seen. Cl ar deviations are observed
especially for the highest SV2C-p p ide concentration tested (5000 nM) between the simulation and
the measured curves. Giv n the r ported kin tic binding da a, the binding responses should begin
reaching equilibrium as can e seen by a clear flattening of the binding curv for the simulati n (A).
However, the measured binding response at 5000 nM SV2C-peptide is not reach ng equilibrium (B)
indicating that the reported kinetic binding data might be inaccurate.
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